Myriad Genetics, Inc.— Sankey Diagram

Quarterly mode · period ending 2025-12-31 · SEC EDGAR

ComparingFY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)
Revenue
$825M
↓-1.6% -$13Mvs FY2024 (Q1+Q2+Q3+Q4)
Gross Profit
$577M
↓-1.5% -$9Mvs FY2024 (Q1+Q2+Q3+Q4)
Operating profit
$415M
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
Reconciled values per the quarterly mode pipeline. Compare against SEC EDGAR filings.
Line itemFY2025 (Q1+Q2+Q3+Q4)FY2024 (Q1+Q2+Q3+Q4)
Revenue$825M$838M
COGS$248M$252M
Gross Profit$577M$585M
R&D$107M$113M
SG&A$0$425M
D&A$54M$61M
Other OpEx$800K$0
Operating Income$415M$0
Interest Exp.$11M$0
Other Non-Op$405M$0
Pretax Income$0$0
Tax$0$0
Net Income$0$0

QuarterCharts · SEC EDGAR data · MYGN · Comparing FY2025 (Q1+Q2+Q3+Q4) vs FY2024 (Q1+Q2+Q3+Q4)